All news

Superbugs under the microscope as international experts gather at Queen’s


Scientists from across Europe who are leading the fight against superbugs will gather at Queen’s University Belfast next week (14-15 September 2016).

They will join researchers from Queen’s who are pioneering a new approach in the ‘arms race’ against antibiotic resistant infections.

Queen’s scientists are working towards the development of new therapies to boost the body’s own defenses against infection, rather than trying to beat the bugs by attacking them directly with antibiotics.

The approach is called ‘host directed therapeutics’ and it focusses on identifying the ‘achilles heel’ within the immune system that allows infection-causing microbes to take hold.

It is one of the approaches that will be discussed during the two-day event, hosted by Professor Jose Bengoechea, Director of Centre for Experimental Medicine at Queen’s.

Professor Bengoechea’s research into combatting the multidrug-resistant microbe Klebsiella Pneumoniae is recognised worldwide.

The conference marks the end of the four-year INBIONET programme (Infection Biology Training Network), which is led by Queen’s and funded by the Marie Curie Initial Training Network Scheme as part of the EU’s Seventh Framework Programme.

For further information on the conference click here.

Media inquiries to Anne-Marie Clarke (Mon-Wed) or Michelle Cassidy (Thu-Fri) at Queen’s Communications Office, T: +44 (0)28 9097 5310 E:

More news and features


Queen’s and University of Toronto to develop future leaders in cancer care for Northern Ireland

20/10/2016 - Queen’s University Centre for Cancer Research and Cell Biology (CCRCB) has announced an innovative Clinical Doctoral Training Programme in Precision Cancer Medicine with the world renowned Princess Margaret Cancer Centre, University of Toronto.


Fighting bowel cancer with fitness

17/10/2016 - A Queen’s University scientist is bringing a new clinical trial to the UK that could help patients with bowel cancer reduce the risk of their disease coming back after treatment.